Navigation Links
Ranbaxy Laboratories All Set To Export Bird Flu Vaccines

In view, of the ever-increasing threat about bird flu worldwide, there has been a healthy competition among several pharmaceutical companies to manufacture the drug.// Ranbaxy Laboratories has become the first Indian company to start shipments of generic version of bird flu drug, Tamiflu. The drug is believed to get shipped to a country where the patent held by the Swedish major Roche would be invalid.

We have sent small quantities of the avian flu drug to a government, where Roche has no patent on the drug', said Dr Brian Tempest, CEO of Ranbaxy and managing director of Ranbaxy. The company has already developed the chemistry to produce the drug and scaled it up to a certain level for sending supplies to another government.

The company is expecting a feedback from Roche regarding sub-licensing for supplying drug to other countries. The patent for the avian flu drug (Tamiflu) is being held by the Swedish manufacturer in most of the countries. Four main pharmaceutical companies including Teva Pharmaceuticals, Mylan Laboratories, Barr Laboratories and Ranbaxy have been in talks with the drug company to manufacture a generic version of the patented drug.

The worldwide demand for the flu drug and concerns regarding the outbreak of an epidemic has prompted for relaxation for rules regarding the drug manufacture. Owing to the above situation, Roche has been subjected to extreme pressure from several Governments across the world.


'"/>




Page: 1

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Ranbaxy gets US FDA approval for Lisinopril
3. Ranbaxy Labs Entry Into Anti-Acne Market
4. Ranbaxy trying to make inroads in herbal drugs market
5. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
6. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
7. Ranbaxy opens Drug discovery centre in Gurgaon
8. SRL Ranbaxy offers quicker bird flu diagnostic test
9. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
10. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
11. Ranbaxy Expands By Acquiring A Generic Company In Belgium
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... ... December 05, 2016 , ... As renowned, board-certified dermatologists, Dr. Sabrina G. Fabi ... patients who do not do their research and undergo cosmetic dermatology treatments from unqualified ... midst of a renaissance and every other month a new treatment or device is ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... CardioQuick Patch® significantly improves the reproducibility and accuracy of placing precordial electrodes with ... , Over the last 60 years, studies have shown that single electrode ...
(Date:12/4/2016)... ... ... James Earl Jones is known for myriad roles on stage and screen, he has ... the forthcoming episodes examines mammogram techniques; a very important part of preventative medicine. , ... detection. Like any other disease, treatments have a much higher chance of success if ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who wish to gain ... of a cosmetic procedure known as Carbon Dioxide (C02) Fractional Laser Resurfacing ... age spots, fine lines, uneven coloration, wrinkles, scarring, skin laxity or textural ...
(Date:12/2/2016)... ... 02, 2016 , ... Lori G. Cohen and Sara K. ... at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference , ... of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , December 5, 2016 PharmaBoardroom today releases ... . ... This report offers companies, investors, policymakers, and stakeholders crucial insight ... of Europe , home to some of the world,s ... pharmaceutical companies in Novartis and Roche, and with a number one ranking ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. 5, 2016 ... treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete ... better safety and tolerability profile of ropeginterferon alfa-2b versus HU ... and the ongoing long-term follow-up trial CONTINUATION-PV to obtain European ... intends to present this data to the FDA as it ...
(Date:12/4/2016)... Attorney General of Louisiana , Charles ... firm of Kahn Swick & Foti, LLC ("KSF"), announces that ... LCI ). On November 3, ... in Generic-Drug Probe to Be Filed by Year-End," which reported ... two years ago, now spans more than a dozen companies," ...
Breaking Medicine Technology: